Sector ETFs — End-of-Day Verdict
NO ACTION (0 acquire, 0 dispose). Three sector gauges cleared the 65 adj-conviction floor for the first time this week (XLF 72, XLI 72, XLV 67) -- but all three are the same un-actionable shape: at-market entries on the FailedBreakdown_Up_20D family (which has never hit a 4-week target on this book, 0/9) with flat-to-inverted model forwards and no valuation offset (blind ETF book). XLF's number rose only because its clean PullbackBuy limit degraded into an at-market chase; XLI is a fresh-flip head-fake; XLV re-prints the inverted forward already refused 07-23. XBI (adj 59) is sub-floor and a +4.5% buy-stop chase. Seventh straight session with no executable setup; fully preserved, 0%.
Recommendations
0 to acquire · 0 to dispose
| Ticker | Name | Close | Action | Action Price Where to act — a buy-limit on a pullback or a buy-stop above resistance, not the current price. Sanity-check vs Close: on a held name, an action price stranded above the close means the queued level was set when the stock was higher — stale, awaiting reprice. | Stop The risk-defined exit, set below the entry for a long (~1.2–1.8×ATR). A held long whose Stop sits at/above the Close is already below its stop — a stale box awaiting reprice. | 1wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | 4wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | 12wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | Rationale |
|---|---|---|---|---|---|---|---|---|---|
| XLF | Financial Select Sector SPDR | 56.31 | WATCH | 56.31 | 55.69 | 56.07 (-0.4%) | 56.21 (-0.2%) | 55.16 (-2.0%) | XLF climbed W61->B61->B61->BUY75 (Buy_Rank 1, adj 75-3 SE-1 =72, clears the 65 floor) -- but it is un-actionable and its setup DEGRADED as conviction rose: 07-23 it was a clean PullbackBuy_VWAP buy-limit @55.59 below close; 07-24 it has morphed into an at-market FailedBreakdown_Up_20D entry @56.31 (=close, dATR -0.0) on the book's actionable-negative family (SE-1, hit_4w 0/9). The model forward is inverted at every horizon (Est_1W 56.07 -0.4%, Est_4W 56.21 -0.2%, Est_12W 55.16 -2.0%, all below entry; Target_12Week 55.16 < entry). No valuation offset (blind book), no below-close limit to queue. Trade Target_Price 57.56 is the risk objective, not the forward view. Re-arm: raw cv>=65 with E4W/E12W back above entry and ideally a live below-close PullbackBuy limit. |
| XLI | Industrial Select Sector SPDR | 182.66 | WATCH | 182.66 | 181.25 | 182.66 (+0.0%) | 180.40 (-1.2%) | 182.47 (-0.1%) | XLI AV59->AV59->W64->BUY75 (Buy_Rank 2, adj 72, clears the 65 floor) -- but this is a textbook fresh single-session flip from WATCH (AVOID before that) straight to BUY on the discounted FailedBreakdown_Up_20D family = the head-fake signature the book keeps fading (cf XLE, MAGS lapse; L1/L4). Entry at-market @182.66 (=close, dATR -0.0), forward flat-to-negative (Est_1W 182.66 =entry, Est_4W 180.40 -1.2%, Est_12W 182.47 -0.1%). Family hit_4w 0/9 on this book. No valuation offset (blind). Re-arm: a 2nd+ stable BUY print at raw cv>=65 with a non-inverted forward. |
| XLV | Health Care Select Sector SPDR | 162.57 | WATCH | 162.57 | 161.33 | 162.40 (-0.1%) | 159.88 (-1.7%) | 156.25 (-3.9%) | XLV holds a 2nd BUY70 print (FailedBreakdown_Up_20D, Buy_Rank 3, adj 67, clears the 65 floor by 2) -- but it re-prints the exact inverted-forward setup already refused 07-23: at-market @162.57 (=close), with the fullest inversion of the three floor-clearers (Est_1W 162.40 -0.1%, Est_4W 159.88 -1.7%, Est_12W 156.25 -3.9%, all below entry). Discounted family (SE-1, hit_4w 0/9), no valuation offset (blind). Trade Target_Price 167.53 is the risk objective, not the forward view. Re-arm: raw cv>=65 with E4W/E12W back above entry. |
| XBI | SPDR S&P Biotech ETF | 150.48 | WATCH | 157.29 | 152.53 | 151.03 (-4.0%) | 155.89 (-0.9%) | 161.70 (+2.8%) | XBI prints BUY on PullbackBuy_VWAP (the book's most reliable cell, bias +0) but fails twice: adj cv59 is 6 below the 65 floor, and despite the pullback label the entry is a buy-STOP @157.29 = +1.66 ATR ABOVE the 150.48 close, a +4.5% chase (L1/L4 discount chases). Real longer forward (Est_4W 155.89, Est_12W 161.70 +7.5%) but conviction + chase-entry gate the trade. Not queued. Re-arm at raw cv>=65 with the entry back below close. |
| — | Sector ETFs | — | NO ACTION | — | — | n/a | n/a | n/a | EOD 2026-07-24 verdict: NO ACTION (0 acquire, 0 dispose). Three sector gauges cleared the 65 adj-conviction floor for the first time this week (XLF 72, XLI 72, XLV 67) but all are the same un-actionable shape -- at-market entries on the FailedBreakdown_Up_20D family (0/9 at 4wk on this book) with flat-to-inverted model forwards and no valuation offset (blind ETF book). XLF's number rose only because its clean PullbackBuy limit degraded into an at-market chase; XLI is a fresh-flip head-fake; XLV re-prints the inverted forward refused 07-23. XBI (adj 59) is sub-floor and a +4.5% buy-stop chase. Flat gauge book, no holdings, monitor clean, no queues open. Seventh straight session without an executable setup; fully preserved, 0%. |
Outcome & track record